Ex Vivo Venetoclax Sensitivity Testing Predicts Response and Overall Survival in De Novo and s/R/R AML Patients Treated with Azacitidine and Venetoclax
Year: 2022
Type: article
Source: Blood
Authors: Sari Kytölä, Ida Vänttinen, Tanja Ruokoranta, Annasofia Holopainen, Anu Partanen, Milla E.L. Kuusisto, Sirpa Koskela, Riikka Räty, Maija Itälä-Remes, Amanda Ranta, Minna Suvela, Alun Parsons, Imre Västrik, Sanna M. Siitonen, Kimmo Porkka, Krister Wennerberg, Caroline A. Heckman, Pia Ettala, Johanna Rimpiläinen, Timo Siitonen, Marja Pyörälä, Heikki Kuusanmäki, Mika Kontro
Institutions: Helsinki University Hospital, University of Helsinki, Institute for Molecular Medicine Finland, HiLIFE – Elämäntieteiden Instituutti, Kuopio University Hospital, Oulu University Hospital, University of Oulu, Tampere University Hospital, Turku University Hospital, University of Copenhagen, Finnish Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310163426